

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天 辰 生 物

LongBio Pharma (Suzhou) Co., Ltd.

天辰生物醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1779)

VOLUNTARY ANNOUNCEMENT
TOPLINE DATA FROM THE PHASE II CLINICAL TRIAL IN CHINA
OF LP-005 FOR THE TREATMENT OF PNH

This announcement is made by LongBio Pharma (Suzhou) Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Group about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that topline data from the Phase II clinical trial (the “**Phase II Clinical Trial**”) in China of LP-005, a bifunctional antibody fusion protein targeting C5 and C3b complement independently developed by the Group, for the treatment of paroxysmal nocturnal hemoglobinuria (“**PNH**”), have been read out. The topline data demonstrated potent efficacy of LP-005 and a favourable safety and tolerability profile.

ABOUT LP-005

LP-005 is the first product of the Group’s bifunctional antibody development platform and a bifunctional antibody fusion protein targeting C5 and C3b complement. As a multi-target complement inhibitor, LP-005 acts on multiple key nodes of the complement cascade simultaneously and comprehensively inhibits all three complement signaling pathways, namely the classical pathway, the alternative pathway and the lectin pathway. Compared with single-target inhibitors, it is expected to more comprehensively block the complex pathological mechanisms of diseases. Potential indications of LP-005 include complement-mediated autoimmune diseases such as PNH, complement-mediated kidney diseases, and periodontitis.

ABOUT PNH

PNH is a rare acquired clonal hematopoietic stem cell disorder characterized primarily by chronic intravascular hemolysis, thrombosis and bone marrow failure. Patients often present with symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea and anemia, and may experience major adverse vascular events. Existing complement inhibitor therapies have improved patients’ clinical outcomes to a certain extent.

LP-005 is a novel bifunctional fusion protein, and it can inhibit both the proximal and terminal complement pathway with a long half-life.

THE PHASE II CLINICAL TRIAL

The Phase II Clinical Trial is a multicenter, randomized, open-label Phase II clinical study conducted in China (Registration No.: CTR20242478), designed to evaluate the efficacy, safety and pharmacokinetic characteristics of LP-005 injection in the treatment of patients with PNH. The trial comprises three dose cohorts of 900 mg, 1,200 mg and 1,500 mg, with subjects receiving intravenous drip infusion once every 4 weeks (Q4W) for a total treatment duration of 48 weeks.

The primary endpoints of the Phase II Clinical Trial include: (i) the change from baseline in serum lactate dehydrogenase (“**LDH**”) level at Week 12 after dosing; and (ii) the proportion of patients with an increase of ≥ 2 g/dL in hemoglobin (“**Hb**”) level from baseline without transfusion at Week 24 after dosing.

TOPLINE DATA

A total of 30 patients with PNH were enrolled in the Phase II Clinical Trial and 27 patients completed 24-week treatment.

At Week 12, LDH levels decreased significantly from baseline. The hemolysis control rate (LDH below $1.5 \times$ upper limit of normal (“**ULN**”)) reached 100% in both the 1,200 mg and 1,500 mg dose groups. A 100% transfusion avoidance rate was achieved, and no breakthrough hemolysis (“**BTH**”) was observed across all three dose groups.

At Week 24 in the 1,500 mg group, 85.7% of patients (6/7) achieved a hemoglobin increase of ≥ 2 g/dL without transfusion, 71.4% of patients (5/7) had hemoglobin ≥ 120 g/L. Transfusion avoidance was 100% (7/7) and no BTH was observed.

LP-005 demonstrated potent hemolysis control and Hb improvement.

Table 1: Key Efficacy Endpoints at Week 12

Endpoint	900 mg (n=10)	1,200 mg (n=10)	1,500 mg (n=10)
LDH change from baseline, LS mean (U/L)	-715.27	-1,472.65	-1,622.77
Hemolysis control (LDH $< 1.5 \times$ ULN)	4 (40.0%)	10 (100%)	10 (100%)
Transfusion avoidance	10 (100%)	10 (100%)	10 (100%)
Breakthrough hemolysis	0	0	0

Note: LDH refers to lactate dehydrogenase; LS mean refers to least squares mean.

In terms of safety, no treatment-related serious adverse event (SAE) was reported. LP-005 demonstrated an overall favourable safety and tolerability profile.

The Board believes that the topline data of the Phase II Clinical Trial validate the competitive efficacy advantages of LP-005 as a dual-target complement inhibitor together with a favourable safety and tolerability profile, and a Q4W dosing interval reflecting the long-acting advantage of LP-005. These results support the further advancement of LP-005 into clinical development.

ABOUT THE COMPANY

The Company is a clinical-stage biopharmaceutical company. Established in 2020 and located in Shanghai and Changshu, Suzhou, China, the Company primarily focuses on in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases. The Group has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases.

The Company cannot guarantee that it will be able to develop and/or ultimately market LP-005 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
LongBio Pharma (Suzhou) Co., Ltd.
Dr. Liu Heng
Chairman of the Board and Executive Director

Hong Kong, October 21, 2026

As at the date of this announcement, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di and Mr. XUE Kailu as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.